Intranasal Immunization with 54 kDa Hemagglutinin Pili Protein of Streptococcus pneumonia Increases Mucosal and Systemic Antibodies

Abstract

Streptococcus pneumoniae (Klein, 1884) can cause disease with high morbidity and mortality in children under 2 yr of age, parents, and individuals with low immunity. Amount one of the diseases that can be caused by these bacteria is pneumonia. To prevent the spread of pneumonia, intranasal immunization has been developed in several studies because of its ability to improve mucosal and systemic immune responses. To prevent the attachment of bacteria to the epithelial surface of the respiratory tract, it would be more effective if intranasal immunization uses a vaccine from bacterial pili protein. The purpose of this study was to conducted to determine the ability of S. pneumoniae bacterial pili protein with a molecular weight of 54 kDa in increasing the concentration of mucosal and systemic antibodies through intranasal administration. Setting and design in this study using pure 54 kDa pili protein was used as an antigen to immunize Wistar mice. Mucosal antibodies were identified by the presence of sIgA in nasal washings and systemic antibodies determined from serum IgA and IgG. Statistical analysis used ANOVA. Mice immunized with combination adjuvant–antigens had higher levels of sIgA, IgA, and IgG than other groups. ANOVA statistical tests showed significant differences in sIgA and IgA levels between rats immunized with antigen–adjuvants and other groups. However, there is no significant difference from serum IgG. This study showed an intranasal immunization of 54 kDa hemagglutinin pili protein S. pneumoniae increased the concentration of sIgA, serum IgA and IgG.